A. Spanevello (Cassano Murge, Italy), V. Brusasco (Genova, Italy)
Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids?
E. Pronina, A. Vizel, I. Vizel (Kazan, Tatarstan, Russian Federation)
|   |
Does short burst oxygen therapy (SBOT) relieve breathlessness after exercise in patients with severe COPD who are not hypoxaemic at rest?
B. R. ODriscoll, A. S. Pulakal, J. Neill, P. Turkington (Salford, United Kingdom)
| |
Effects of sildenafil on secondary pulmonary hypertension in highlanders with COPD
T. Sooronbaev, G. Kadyraliev, S. Shabykeeva, B. Imanov (Bishkek, Kyrgyzstan)
| |
Relationship between pharmacotherapy and severity of disease in patients with COPD
B. Werner, E. Wanka, R. A. Jörres, D. Nowak, M. Pfeifer (Munich, Donaustauf, Germany)
| |
Evaluation of mucociliary clearance‘s (MCC) condition in patients with COPD. Influence of tiotropium bromide (TB) on MCC
O. Gurzhiy, T. Pertseva, O. Lykholat (Dnepropetrovsk, Ukraine)
| |
Effect of formoterol addition on dynamic hyperinflation during 6-minute walk test (6MWT) in moderate to severe COPD
D. Moreno, Z. Fuentes, M. Montes de Oca, T. Martín, C. Tálamo, G. Levy, M. Carrabs, A. Acuña (Caracas, Venezuela)
| |
Bronchodilator reversibility testing in COPD using an inspiratory peak flow meter
S. Korn, O. Kornmann, A. Eich, L. Rydzy, M. Sebastian, R. Joerres, R. Buhl, C. Taube (Mainz, Munich, Germany)
| |
The effect of diuretics on plasma brain natriuretic peptide level in patients with acute exacerbations of chronic obstructive pulmonary disease
F. Kanat, H. Vatansev, T. Teke (Konya, Turkey)
| |
Night treatment with long acting ß2 agonists in mild COPD patients with sleep apnoea syndrome
I. Kopitovic, B. Andjelic, M. Drvenica-Jovancevic (Sremska Kamenica, Serbia And Montenegro)
| |
Respiratory day care unit effectiveness in COPD management
A. Llunell, J. Sans, M. Somoza, J. Armengol, J. Rios, R. Prieto (Terrassa, Barcelona, Barcelona, Spain)
| |
Are nebulized bronchodilators (NB) always prescribed according to international standards in a French chest department?
C. Clement-Duchene, C. Thomassin, F. Vlastos, Y. Martinet (Nancy, France)
| |
Comparative clinical-functional effectiveness and cardiological safety of short-acting combined broncholytics in 2 months basic therapy in COPD patients
Y. Feschenko, L. Yashyna, M. Polianska, N. Kramarska (Kiev, Ukraine)
| |
Influence of tiotropium bromide on quantity of exacerbations and survival rate of COPD patients
N. Berdnikova, M. Savelyeva, A. Tsoy (Moscow, Russian Federation)
| |
Efficacy of influenza and pneumococcal vaccinations among patients with COPD
G. Ozgul, G. Ortakoylu, A. Bahadir, F. Alkan, F. Senel, E. Caglar (Istanbul, Turkey)
| |
Anti-inflammatory activity of Erespal (Fenspirid, Servie, France) in COPD patients
E. Bukreeva, S. Nesterovich, O. Akbasheva, G. Seitova, T. Melnik, E. Dementieva (Tomsk, Russian Federation)
| |
Mechanism of decreased ventilatory response to hypercapnia in chronic obstructive pulmonary disease
M. Bruyneel, P. B. Silvia, B. Olivier, A. K. Sophia, D. M. Isabelle, S. Roger, N. Vincent (Brussels, Belgium)
| |
Methionine in COPD treatment
A. Skrahin, A. Astrauko, H. Hurevich, A. Skrahina (Minsk, Belarus)
| |
A clinical scoring algorithm to predict respiratory admissions and mortality in COPD
S. Schembri, W. Anderson, J. Winter, P. Thompson, D. Pettitt, T. MacDonald, J. Winter (Dundee, United Kingdom; NY, United States Of America)
| |
Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment
F. C. Sciurba, R. A. Baumgartner, K. Sciarappa, R. P. Benzo, J. P. Hanrahan (Pittsburgh, PA, Marlborough, MA, United States Of America)
| |